Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi ...

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111 ...